Skip to main content
TipRanks
Go Ultimate75% OFF

Frontage Holdings Corp. (FGHQF) AI Stock Analysis

FGHQF

Frontage Holdings Corp.

(Other OTC:FGHQF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Long-term Revenue ExpansionThe company has demonstrated substantial revenue expansion across the 2020–2025 period, indicating that its real-estate activities can generate meaningful scale over time. The sharp 2025 rebound also shows that demand and transaction activity can recover after periods of uneven performance.
Negative Factors
Compressed Profit MarginsThe sustained decline in gross margin shows that revenue growth has not translated into the same level of underlying profitability as earlier in the cycle. Lower gross economics reduce the cushion available for operating costs and make future earnings more sensitive to transaction conditions and execution.

Frontage Holdings Corp. (FGHQF) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%30%40%FGHQF+17.45%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$4.24B
Dividend Yield
―
Average Volume (3M)
40.50K
Price to Earnings (P/E)
51.0
Beta (1Y)
-0.24
Revenue Growth
10.00%
EPS Growth
173.68%
Country
US
Employees
1,800
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Frontage Holdings Corp. Business Overview & Revenue Model

Company Description

Frontage Holdings Corporation functions as a contract research organization (CRO), delivering a broad spectrum of laboratory and associated services to the pharmaceutical, biotechnology, and agrochemical sectors, alongside performing vital bioequival...

Frontage Holdings Corp. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

FGHQF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:2269HK:226981OutperformHKD 190.63B32.4910.51%―21.93%21.94%
HK:1548HK:154871OutperformHKD 67.32B-12.64-16.23%―53.48%-120.02%
HK:3759HK:375963NeutralHKD 79.93B41.3110.93%0.83%24.21%19.72%
HK:2315HK:231556NeutralHKD 17.02B38.2615.94%―48.04%166.72%
HK:6821HK:682155NeutralHKD 59.72B44.466.66%1.30%23.95%18.73%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%50%100%150%200%FGHQFHK:1548HK:2269HK:3759HK:2315HK:6821Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
FGHQF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
FGHQFFrontage Holdings Corp.0.170.0317.45%
HK:1548Genscript Biotech Corporation29.6213.2981.38%
HK:2269Wuxi Biologics (Cayman) 46.3014.3845.05%
HK:3759Pharmaron Beijing Co., Ltd. Class H27.846.1128.09%
HK:2315Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H38.308.0026.40%
HK:6821Asymchem Laboratories (Tianjin) Co., Ltd. Class H115.0038.2149.77%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.